» Articles » PMID: 36313690

Folate Receptor-positive Circulating Tumor Cells Predict Survival and Recurrence Patterns in Patients Undergoing Resection for Pancreatic Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Oct 31
PMID 36313690
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the prognostic impact of folate receptor (FR)-positive circulating tumor cells (FR CTCs) for patients with pancreatic cancer (PC).

Background: Risk stratification before surgery for PC patients remains challenging as there are no reliable prognostic markers currently. FR CTCs, detected by ligand-targeted polymerase chain reaction (LT-PCR), have shown excellent diagnostic value for PC in our previous study and prognostic value in a variety of cancer types.

Methods: Peripheral blood samples from 44 consecutive patients diagnosed with PC were analyzed for FR CTCs. 25 patients underwent tumor resection and were assigned to the surgical group. 19 patients failed to undergo radical resection because of local advance or distant metastasis and were assigned to the non-surgical group. The impact of CTCs on relapse and survival were explored.

Results: For the prognostic stratification, the optimal cut-off value of CTCs analyzed by receiver operating characteristic (ROC) curve was 14.49 folate units (FU)/3 ml. High CTC levels (> 14.49 FU/3 ml) were detected in 52.0% (13/25) of the patients in the surgical group and 63.2% (12/19) in the non-surgical group. In the surgical group, median disease-free survival (DFS) for patients with high CTC levels versus low CTC levels (< 14.49 FU/3 ml) was 8.0 versus 26.0 months ( = 0.008). In multivariable analysis, CTCs were an independent risk factor for DFS (HR: 4.589, = 0.012). Concerning the recurrence patterns, patients with high CTC levels showed a significantly frequent rate of distant and early recurrence ( = 0.017 and = 0.011). CTC levels remained an independent predictor for both distant (OR: 8.375, = 0.014) and early recurrence (OR: 8.412, = 0.013) confirmed by multivariable logistic regression. However, CTCs did not predict survival in the non-surgical group ( = 0.220).

Conclusion: FR CTCs in resected PC patients could predict impaired survival and recurrence patterns after surgery. Preoperative CTC levels detected by LT-PCR may help guide treatment strategies and further studies in a larger cohort are warranted.

Citing Articles

Circulating tumor cells in pancreatic cancer: The prognostic impact in surgical patients.

Teja M, Ocanto A, Counago F World J Clin Oncol. 2024; 15(8):987-991.

PMID: 39193164 PMC: 11346077. DOI: 10.5306/wjco.v15.i8.987.


Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis.

Chu X, Zhong X, Zang S, Wang M, Li P, Ma Y Front Oncol. 2024; 14:1327280.

PMID: 38983932 PMC: 11231205. DOI: 10.3389/fonc.2024.1327280.


Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis.

Zhang Z, Bao Y, Zhao Y, Wang J, Guo J, Sun S World J Clin Oncol. 2023; 14(11):504-517.

PMID: 38059182 PMC: 10696218. DOI: 10.5306/wjco.v14.i11.504.


Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.

Pedrazzoli S J Clin Med. 2023; 12(20).

PMID: 37892599 PMC: 10607532. DOI: 10.3390/jcm12206461.

References
1.
Honselmann K, Pergolini I, Fernandez-Del Castillo C, Deshpande V, Ting D, Taylor M . Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2020; 272(2):357-365. PMC: 6639153. DOI: 10.1097/SLA.0000000000003123. View

2.
Salvianti F, Gelmini S, Mancini I, Pazzagli M, Pillozzi S, Giommoni E . Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. Br J Cancer. 2021; 125(1):94-100. PMC: 8257609. DOI: 10.1038/s41416-021-01399-6. View

3.
Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

4.
Chen C, Ke J, Zhou X, Yi W, Brunzelle J, Li J . Structural basis for molecular recognition of folic acid by folate receptors. Nature. 2013; 500(7463):486-9. PMC: 5797940. DOI: 10.1038/nature12327. View

5.
Connor A, McNamara K, Al-Sukhni E, Diskin J, Chan D, Ash C . Central, But Not Peripheral, Circulating Tumor Cells are Prognostic in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Ann Surg Oncol. 2015; 23(7):2168-75. DOI: 10.1245/s10434-015-5038-6. View